Indivumed, a worldwide leading biotechnical company in the field of personalized cancer medicine, and Intermed, a medical trading and logistics company, will join forces in the field of personalized cancer medicine in the future. Intermed, as an affiliated partner company, also performs services for LADR Der Laborverbund Dr. Kramer & Kollegen.
Intermed invests and participates in Indivumed in order to accelerate the expansion of Indivumed's worldwide leading Cancer Database in Germany and, in addition, to distribute through the physician-managed LADR Laborverbund innovative cancer diagnostic test's offered by Indivumed's subsidiary Indivutest GmbH.
"As a result of the alliance formed with Intermed, we are very glad to receive logistical support for the expansion of our cancer database and, at the same time, be able to provide Central-European wide highly-innovative diagnostic tests for personalized cancer medicine," says Prof. Dr. med. Hartmut Juhl, founder and chief executive officer of Indivumed GmbH.
Prof. Dr. med. Jan Kramer, owner and managing director of Intermed and of LADR Der Laborverbund Dr. Kramer & Kollegen, emphasizes that, "By investing in Indivumed GmbH, we partner with one of the leading companies in the field of personalized medicine."
With the worldwide leading cancer database, Indivumed holds an essential scientific key solution for further development of personalized cancer medicine. This has been demonstrated by Indivumed's participation in the development of the new, groundbreaking diagnostic field of 'Liquid Biopsy'. "We are looking forward to partner with IndivuTest GmbH, making available to patients new, highly innovative diagnostic tests through our LADR laboratory network and the logistical possibilities of Intermed across the nation," continues Professor Kramer.
Indivumed, intermed form alliance to develop personalized cancer medicine
.jpg)
